# UNITED THERAPEUTICS Corp (UTHR)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/united-therapeutics-corp/ JSON: https://steadybase.io/company/united-therapeutics-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: UNITED THERAPEUTICS Corp
- Ticker: UTHR (Nasdaq)
- SEC CIK: 0001082554
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Silver Spring, MD
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: unither.com
- LinkedIn: https://www.linkedin.com/company/unitedtherapeutics
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $3.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.html
- Operating income: $1.5B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.html
- Net income: $1.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.html
- SG&A: $755.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.html
- Employees: 1,400 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Shares outstanding: 42,588,726 as of Oct 28, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/0001082554-26-000035-index.html
- Auditor: Ernst & Young LLP, Tysons, Virginia, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm

## Business

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $3.2B | $1.5B | $1.3B | $755.8M |
| Dec 31, 2024 | $2.9B | $1.4B | $1.2B | $709.7M |
| Dec 31, 2023 | $2.3B | $1.2B | $984.8M | $477.1M |
| Dec 31, 2022 | $1.9B | $979.7M | $727.3M | $482.1M |
| Dec 31, 2021 | $1.7B | $555.9M | $475.8M | $467.0M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/united-therapeutics-corp.json

## Officers and directors

- Martine A. Rothblatt, Chairperson & CEO. Source: Form 4 filed Sep 30, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000110657826000152/0001106578-26-000152-index.htm
- James Edgemond, CFO AND TREASURER. Source: Form 4 filed Jun 23, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000163617826000029/0001636178-26-000029-index.htm
- James C. Edgemond, Chief Financial Officer and Treasurer. LinkedIn: https://linkedin.com/in/james-edgemond-55795426. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- United Therapeutics, Michael Benkowitz , President and Chief Operating Officer of. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/uthrq32026-ex991.htm
- Michael Benkowitz, PRESIDENT AND COO. LinkedIn: https://linkedin.com/in/michael-benkowitz-a962954. Source: Form 4 filed May 14, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000167323226000014/0001673232-26-000014-index.htm
- Judy D. Olian, President Emerita, Quinnipiac University. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Louis Sullivan, President Emeritus, Morehouse School of Medicine; Former Secretary, U.S. Department of Health and Human Services. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Paul A. Mahon, EVP & GENERAL COUNSEL. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000123158926000020/0001231589-26-000020-index.htm
- Ray Kurzweil, Chief AI Officer and Co-Founder, Beyond Imagination. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Victor Dzau, M.D., member of the Board. Source: 8-K filed Jul 23, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000110465926086068/tm2620809d1_8k.htm
- Christopher Causey, Former Consultant and Healthcare Executive. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Christopher Patusky, Founding Principal, Patusky Associates, LLC. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Jan Malcolm, Former Commissioner of Health, State of Minnesota. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Linda Maxwell, Surgeon; Operating Partner, DCVC. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Nilda Mesa, Adjunct Professor, Columbia University; Former Director, NYC Mayor's Office of Sustainability. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Raymond Dwek, Emeritus Director, Oxford Glycobiology Institute, Oxford University. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Richard Giltner, Former Portfolio Manager at Lyxor Asset Management, an asset management group at Société Générale, S.A.. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- Tommy Thompson, Former Governor of Wisconsin; Former Secretary, U.S. Department of Health and Human Services. Source: 10-K filed Feb 25, 2026, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/uthr-20261104.htm
- Oct 22, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926117964/tm2628087d1_8k.htm
- Oct 14, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/tm2627546d1_8k.htm
- Sep 8, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926105953/tm2624887d1_8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthr-20260805.htm
- Jul 23, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926086068/tm2620809d1_8k.htm
- Jun 29, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926078865/tm2619258d1_8k.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000021/uthr-20260506.htm
- Mar 30, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/tm2610558d1_8k.htm
- Mar 9, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926025331/tm268321d1_8k.htm

## Insider trades (Form 4)

- Nov 6, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 9,500 shares, about $5.4M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000183/0001106578-26-000183-index.htm
- Nov 5, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 1,960 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000182/0001106578-26-000182-index.htm
- Nov 5, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 7,540 shares, about $4.3M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000181/0001106578-26-000181-index.htm
- Nov 5, 2026: Paul A. Mahon (EVP & GENERAL COUNSEL) sold 8,300 shares, about $5.0M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000123158926000023/0001231589-26-000023-index.htm
- Nov 4, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 1,723 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000180/0001106578-26-000180-index.htm
- Nov 4, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 7,777 shares, about $4.7M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000179/0001106578-26-000179-index.htm
- Nov 3, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 9,500 shares, about $5.7M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000178/0001106578-26-000178-index.htm
- Nov 2, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 9,500 shares, about $5.7M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000177/0001106578-26-000177-index.htm
- Oct 30, 2026: Martine A. Rothblatt (Chairperson & CEO) sold 2,938 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/1082554/000110657826000176/0001106578-26-000176-index.htm

## What management said

- "Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization" United Therapeutics, Michael Benkowitz , President and Chief Operating Officer of (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/uthrq32026-ex991.htm

## Latest filings

- 8-K filed Oct 22, 2026: https://www.sec.gov/Archives/edgar/data/1082554/000110465926117964/tm2628087d1_8k.htm
- 10-K filed Feb 25, 2026: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000027/uthr-20260630.htm
- DEF 14A filed Apr 29, 2026: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000009/uthr-20260428.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/